Collecting tumor samples to improve cancer treatment matching

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather archival tumor samples from patients with advanced solid tumors to analyze biomarkers that may inform treatment options. By utilizing next-generation sequencing, the study seeks to identify specific molecular characteristics of cancers, which can help physicians determine the most appropriate clinical trials or approved therapies for individual patients. Additionally, the study aims to establish a province-wide registry of genomic data to enhance cancer care across Ontario.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.
2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.
3. Patient must be ≥ 18 years old.
4. Patient's ECOG performance status equal to 0 or 1.
5. All patients must have a life expectancy of \> 6 months.
6. All patients must have adequate organ functions.
7. All patients must have signed and dated an informed consent form.

Exclusion Criteria:

1\. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.

Where it's running

• The Ottawa Hospital Cancer Centre
  Ottawa, Ontario, Canada Recruiting
• Princess Margaret Hospital
  Toronto, Ontario, Canada Recruiting
• Juravinski Cancer Centre
  Hamilton, Ontario, Canada Active not recruiting
• Kingston General Hospital
  Kingston, Ontario, Canada Active not recruiting
• London Health Sciences Centre
  London, Ontario, Canada Active not recruiting
• Mount Sinai Hospital
  Toronto, Ontario, Canada Active not recruiting

Study contacts

• Principal investigator: Philippe Bedard, MD — Princess Margaret Hospital, Canada
• Study coordinator: Samanta Del Rossi
• Email: samanta.delrossi@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Using blood tests to assess early treatment response in cancer patients

  This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04354064

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• A network for collaborative cancer research in Ontario

  This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.

  Recruiting at 2 sites University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT05403177

• Using nanoparticles to enhance radiation treatment for brain metastases

  This study is testing if adding special nanoparticles to radiation therapy can help people with brain metastases get better results than radiation alone.

  Recruiting at 2 sites Phase 2 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT04899908

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.